Imbruvica
Imbruvica (ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor approved to treat Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease and currently being evaluated in multiple types of cancer and for other serious diseases.
Type of Molecule
Small MoleculeTarget
BTKProduct Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted) |
|---|---|---|
| Follicular Lymphoma | US,EU |
Phase 3
|
| Mantle Cell Lymphoma | n/a |
Phase 3
|